Literature DB >> 2881741

Significance of eosinophil and mast cell counts in rectal mucosa in ulcerative colitis. A prospective controlled study.

S K Sarin, V Malhotra, S Sen Gupta, A Karol, S K Gaur, B S Anand.   

Abstract

Eosinophil and mast cell counts were done in 44 patients with active ulcerative colitis, 10 patients with ulcerative colitis in remission, and 44 matched subjects with functional bowel disorder. Mean (+/- SD) rectal eosinophil counts (EC) per unit area were significantly high (P less than 0.01) in active ulcerative colitis (5.80 +/- 5.49) as compared with inactive disease (2.81 +/- 2.19) or controls (3.01 +/- 1.67). Eosinophil count was not significantly different in the acute stage between responder (6.36 +/- 5.95) and nonresponders (5.1 +/- 5.84) to medical treatment and was thus of little discriminatory and prognostic value. Mean (+/- SD) EC was reduced from 6.36 +/- 5.95 to 3.91 +/- 3.19 in responders after four weeks of medical treatment. There was little change in the EC with treatment in nonresponders. No correlation was seen between tissue eosinophils and clinical severity of ulcerative colitis. Mast cell count was not significantly different between patients with active ulcerative colitis, inactive disease, and controls and thus had little diagnostic or prognostic value. It can be concluded therefore, that EC in the rectal mucosa indicated activity but not severity of ulcerative colitis. A reduction in EC possibly indicated remission. Rectal EC, however, cannot correctly prognosticate the treatment response and outcome of the disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2881741     DOI: 10.1007/bf01296289

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Mast cells and immunoglobulin E in inflammatory bowel disease.

Authors:  G Lloyd; F H Green; H Fox; V Mani; L A Turnberg
Journal:  Gut       Date:  1975-11       Impact factor: 23.059

2.  The prognosis of idiopathic proctitis.

Authors:  J Powell-Tuck; J K Ritchie; J E Lennard-Jones
Journal:  Scand J Gastroenterol       Date:  1977       Impact factor: 2.423

3.  Crohn's disease--mast cell quantitation using one micron plastic sections for light microscopic study.

Authors:  A M Dvorak; R A Monahan
Journal:  Pathol Annu       Date:  1983

4.  Rectal IgE cells in inflammatory bowel disease.

Authors:  D P O'Donoghue; P Kumar
Journal:  Gut       Date:  1979-02       Impact factor: 23.059

5.  Significance of C-reactive protein in the management of ulcerative colitis.

Authors:  M P Sharma; S Sarin; A N Malaviya; M G Karmarkar
Journal:  Indian J Med Res       Date:  1982-06       Impact factor: 2.375

6.  Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study.

Authors:  P C Rosekrans; C J Meijer; A M van der Wal; C J Cornelisse; J Lindeman
Journal:  Gut       Date:  1980-11       Impact factor: 23.059

7.  Eosinophils in the rectal mucosa. A simple method of predicting the outcome of ulcerative proctocolitis?

Authors:  R V Heatley; P D James
Journal:  Gut       Date:  1979-09       Impact factor: 23.059

8.  Rectal mucosal plasma cells in inflammatory bowel disease.

Authors:  B B Scott; A Goodall; P Stephenson; D Jenkins
Journal:  Gut       Date:  1983-06       Impact factor: 23.059

9.  Disodium cromoglycate in the treatment of ulcerative colitis and Crohn's disease.

Authors:  V Binder; L Elsborg; J Greibe; C Hendriksen; L Høj; K B Jensen; E Kristensen; J R Madsen; B Marner; P Riis; L Willumsen
Journal:  Gut       Date:  1981-01       Impact factor: 23.059

10.  Ulcerative colitis in a North Indian hospital: current trends.

Authors:  M P Sharma; S K Sarin
Journal:  J R Coll Physicians Lond       Date:  1985-04
View more
  15 in total

Review 1.  Mucosal mast cells are pivotal elements in inflammatory bowel disease that connect the dots: stress, intestinal hyperpermeability and inflammation.

Authors:  Ashkan Farhadi; Jeremy-Z Fields; Ali Keshavarzian
Journal:  World J Gastroenterol       Date:  2007-06-14       Impact factor: 5.742

2.  CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis.

Authors:  Maria Lampinen; Amanda Waddell; Richard Ahrens; Marie Carlson; Simon P Hogan
Journal:  J Leukoc Biol       Date:  2013-07-31       Impact factor: 4.962

3.  Soluble CD14 is essential for lipopolysaccharide-dependent activation of human intestinal mast cells from macroscopically normal as well as Crohn's disease tissue.

Authors:  Sibylle A Brenner; Steffi Zacheja; Michael Schäffer; Katharina Feilhauer; Stephan C Bischoff; Axel Lorentz
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

Review 4.  Eosinophilic Esophagitis Clinical Manifestations and Differential Diagnosis.

Authors:  Diana Muñoz-Mendoza; Adrián Chapa-Rodríguez; Sami L Bahna
Journal:  Clin Rev Allergy Immunol       Date:  2018-08       Impact factor: 8.667

5.  Colonic mucosal mast cell distribution at line of demarcation of active ulcerative colitis.

Authors:  T King; W Biddle; P Bhatia; J Moore; P B Miner
Journal:  Dig Dis Sci       Date:  1992-04       Impact factor: 3.199

6.  Antibody to eosinophil cationic protein suppresses dextran sulfate sodium-induced colitis in rats.

Authors:  Kazuko Shichijo; Kazuya Makiyama; Chun-Yang Wen; Mutsumi Matsuu; Toshiyuki Nakayama; Masahiro Nakashima; Makoto Ihara; Ichiro Sekine
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

7.  Evaluation of mucosal eosinophils in the pediatric colon.

Authors:  Licia Pensabene; Marie-Anne Brundler; Juliane M Bank; Carlo Di Lorenzo
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

8.  Lack of crucial role of mast cells in pathogenesis of experimental colitis in mice.

Authors:  A Minocha; C Thomas; R Omar
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

9.  Ketotifen effectively prevents mucosal damage in experimental colitis.

Authors:  R Eliakim; F Karmeli; E Okon; D Rachmilewitz
Journal:  Gut       Date:  1992-11       Impact factor: 23.059

10.  Changes of colonic vasoactive intestinal peptide and cholinergic activity in rats with chemical colitis.

Authors:  S Kishimoto; H Kobayashi; S Shimizu; K Haruma; T Tamaru; G Kajiyama; A Miyoshi
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.